IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2022i1p758-d1021468.html
   My bibliography  Save this article

Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma—An Indian Perspective of 212 Patients

Author

Listed:
  • Amrit Kaur Kaler

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Khushi Patel

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Harshali Patil

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Yash Tiwarekar

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Bijal Kulkarni

    (Department of Pathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Meenal Hastak

    (Department of Pathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Nivetha Athikari

    (Department of Pathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Samrudhi Rane

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Ankita Nikam

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Smita Umarji

    (Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Imran Shaikh

    (Department of Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Sandeep Goyle

    (Department of Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

  • Rajesh Mistry

    (Department of Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai 400053, India)

Abstract

Lung cancer is the world’s leading cause of cancer-related deaths. Epidermal growth factor receptor (EGFR) is one of the critical oncogenes and plays a significant role in tumor proliferation and metastasis. Patients with sensitizing mutations in the EGFR gene have better clinical outcomes when treated with tyrosine kinase inhibitors (TKI). This study expands our knowledge of the spectrum of EGFR mutations among lung cancer patients in the Indian scenario. This is a retrospective descriptive study of all newly diagnosed patients with lung cancer in tertiary care hospital in India. All the samples were subjected to real-time PCR (q-PCR) analysis and confirmation of rare novel mutations was done using Sanger sequencing. Clinicopathological characteristics, mutational EGFR status, and location on the exon and metastatic sites were evaluated. An analysis of total 212 samples showed mutations in 38.67% of cases. Among these, five (5.9%) samples had mutations in exon 18, 41 (48.8%) samples had mutations in exon 19, 12 (14.28%) samples had mutations in exon 20, and 26 (30.95%) samples had mutations in exon 21. Eleven (13.41%) were found to be uncommon EGFR mutations. Additionally, six (21.4%) samples that had EGFR mutations were also positive for brain metastasis. Future testing on bigger panels will help to characterize the incidence of genetic mutations and to determine the appropriate targeted treatment choices for NSCLC patients.

Suggested Citation

  • Amrit Kaur Kaler & Khushi Patel & Harshali Patil & Yash Tiwarekar & Bijal Kulkarni & Meenal Hastak & Nivetha Athikari & Samrudhi Rane & Ankita Nikam & Smita Umarji & Imran Shaikh & Sandeep Goyle & Raj, 2022. "Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma—An Indian Perspective of 212 Patients," IJERPH, MDPI, vol. 20(1), pages 1-11, December.
  • Handle: RePEc:gam:jijerp:v:20:y:2022:i:1:p:758-:d:1021468
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/1/758/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/20/1/758/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2022:i:1:p:758-:d:1021468. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.